Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-2: vepugratinib versus placebo with enfortumab vedotin and pembrolizumab in FGFR3-altered advanced urothelial cancer
NL-OMON61066Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) and bladder cancer comparing Vepugratinib + enfortumab vedotin + pembrolizumab with Placebo + enfortumab vedotin + pembrolizumab (2 arms). Primary endpoints: Safety and tolerability of vepugratinib in combination with enfortumab vedotin and pembrolizumab, Overall response rate and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
vepugratinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON61066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61066.